Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer
- PMID: 32352489
- DOI: 10.1001/jamaoncol.2020.0637
Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer
Comment in
- 
  
  Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer-Reply.JAMA Oncol. 2020 Jul 1;6(7):1116-1117. doi: 10.1001/jamaoncol.2020.0646. JAMA Oncol. 2020. PMID: 32352479 No abstract available.
Comment on
- 
  
  Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.JAMA Oncol. 2020 Mar 1;6(3):375-384. doi: 10.1001/jamaoncol.2019.5367. JAMA Oncol. 2020. PMID: 31876895 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
- Full Text Sources
- Medical
 
        